Codexis Current Ratio 2009-2021 | CDXS

Codexis current ratio from 2009 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
Codexis Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2021-06-30 $0.17B $0.02B 7.16
2021-03-31 $0.17B $0.02B 7.70
2020-12-31 $0.18B $0.03B 7.38
2020-09-30 $0.10B $0.02B 5.02
2020-06-30 $0.11B $0.02B 5.62
2020-03-31 $0.12B $0.02B 5.14
2019-12-31 $0.11B $0.02B 7.42
2019-09-30 $0.11B $0.02B 7.37
2019-06-30 $0.11B $0.02B 6.30
2019-03-31 $0.06B $0.02B 3.42
2018-12-31 $0.07B $0.02B 3.77
2018-09-30 $0.07B $0.02B 3.88
2018-06-30 $0.07B $0.02B 4.04
2018-03-31 $0.04B $0.02B 1.67
2017-12-31 $0.05B $0.03B 1.81
2017-09-30 $0.04B $0.02B 2.05
2017-06-30 $0.04B $0.01B 3.05
2017-03-31 $0.02B $0.01B 1.61
2016-12-31 $0.03B $0.01B 2.20
2016-09-30 $0.03B $0.01B 2.57
2016-06-30 $0.03B $0.01B 2.24
2016-03-31 $0.03B $0.02B 1.75
2015-12-31 $0.03B $0.02B 2.21
2015-09-30 $0.03B $0.01B 2.52
2015-06-30 $0.02B $0.01B 1.88
2015-03-31 $0.03B $0.01B 2.33
2014-12-31 $0.03B $0.01B 2.40
2014-09-30 $0.03B $0.01B 2.56
2014-06-30 $0.03B $0.01B 2.49
2014-03-31 $0.03B $0.01B 2.62
2013-12-31 $0.04B $0.01B 3.20
2013-09-30 $0.04B $0.01B 3.98
2013-06-30 $0.04B $0.01B 3.87
2013-03-31 $0.06B $0.02B 3.23
2012-12-31 $0.06B $0.02B 3.67
2012-09-30 $0.08B $0.02B 3.61
2012-06-30 $0.07B $0.02B 3.50
2012-03-31 $0.08B $0.03B 2.43
2011-12-31 $0.08B $0.03B 2.80
2011-09-30 $0.08B $0.03B 2.24
2011-06-30 $0.07B $0.03B 2.62
2011-03-31 $0.08B $0.03B 2.68
2010-12-31 $0.09B $0.03B 3.35
2010-09-30 $0.12B $0.04B 3.29
2010-06-30 $0.12B $0.03B 3.71
2010-03-31 $0.05B $0.04B 1.35
2009-12-31 $0.07B $0.05B 1.32
2009-09-30 $0.00B 0.00
2009-06-30 $0.00B 0.00
2009-03-31 $0.00B 0.00
2008-12-31 $0.00B 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.923B $0.069B
Codexis is a leading protein engineering company that applies its proprietary CodeEvolver technology to develop proteins for a variety of applications, including as biocatalysts for the commercial manufacture of pharmaceuticals, fine chemicals and industrial enzymes, and enzymes as biotherapeutics and for use in molecular diagnostics. Codexis? proven technology enables improvements in protein performance, meeting customer needs for rapid, cost-effective and sustainable manufacturing in multiple commercial-scale implementations of biocatalytic processes.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $127.994B 8.52
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.309B 20.85
Biohaven Pharmaceutical Holding (BHVN) United States $9.150B 0.00
Emergent Biosolutions (EBS) United States $2.677B 6.46
Arcus Biosciences (RCUS) United States $2.522B 0.00
Myovant Sciences (MYOV) United Kingdom $1.905B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.799B 0.00
Zymeworks (ZYME) Canada $1.071B 0.00
Ambrx Biopharma (AMAM) United States $0.474B 0.00
SQZ Biotechnologies (SQZ) United States $0.341B 0.00
Enzo Biochem (ENZ) United States $0.160B 15.76